Tags : Urothelial Cancer

Regulatory

Astellas and Seagen Reports Submission of Two BLA to the

Shots: The first BLA submission is based on P-III EV-301 trial which involves assessing of Padcev vs CT in 600 patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based CT and a PD-1/L1 inhibitor. The 1EP of the study was OS The second BLA submission is based on P-II cohort […]Read More

Pharma

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib

 Shots:  Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial  The focus of the agreement is for the onset of the trial assessing Basilea’s derazantinib in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced (UC) and FGFR genomic defects  Derazantinib (BAL087, formerly ARQ 087) is […]Read More